Literature DB >> 8383784

Growth factor and peptide receptors in small cell lung cancer.

T W Moody1, F Cuttitta.   

Abstract

In the past decade, over 1000 continuous human cell lines have been established from lung cancer biopsy specimens. Numerous growth factors and receptors have been identified in the small cell lung cancer (SCLC) cell lines. SCLC is a neuroendocrine tumor which contains numerous peptides, including bombesin/gastrin releasing peptide (BN/GRP), and receptors. High levels of GRP mRNA and immunoreactivity are present in SCLC cells. The secretion rate of GRP from SCLC cells is increased by vasoactive intestinal peptide (VIP), which elevates the intracellular cAMP. GRP binds to cell surface receptors, elevates cytosolic calcium and stimulates the growth of SCLC cells. Additional SCLC growth factors include insulin-like growth factor I (IGF-I) and transferrin. IGF-I mRNA and protein is present in SCLC. IGF-I binds with high affinity to SCLC cells and stimulates tyrosine kinase activity and growth. Transferrin is also present in SCLC cells. Transferrin binds with high affinity to SCLC cells and stimulates iron transport and growth. Synthetic peptide antagonists and monoclonal antibodies have been identified which disrupt autocrine growth pathways and inhibit SCLC growth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383784     DOI: 10.1016/0024-3205(93)90098-n

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  13 in total

Review 1.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 2.  Anticoagulation, ferrotoxicity and the future of translational lung cancer research.

Authors:  Leo R Zacharski
Journal:  Transl Lung Cancer Res       Date:  2016-06

3.  G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo.

Authors:  A Nagata; M Ito; N Iwata; J Kuno; H Takano; O Minowa; K Chihara; T Matsui; T Noda
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis.

Authors:  R O'Connor; A Kauffmann-Zeh; Y Liu; S Lehar; G I Evan; R Baserga; W A Blättler
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

5.  Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.

Authors:  G Halmos; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

Review 6.  Calcium-mediated signal transduction: biology, biochemistry, and therapy.

Authors:  K Cole; E Kohn
Journal:  Cancer Metastasis Rev       Date:  1994-03       Impact factor: 9.264

7.  Angiogenesis: role of calcium-mediated signal transduction.

Authors:  E C Kohn; R Alessandro; J Spoonster; R P Wersto; L A Liotta
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues.

Authors:  Simone Däpp; Cristina Müller; Elisa García Garayoa; Peter Bläuenstein; Veronique Maes; Luc Brans; Dirk A Tourwé; Roger Schibli
Journal:  EJNMMI Res       Date:  2012-06-09       Impact factor: 3.138

9.  Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours.

Authors:  M Mbikay; F Sirois; J Yao; N G Seidah; M Chrétien
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.

Authors:  J Pinski; A V Schally; G Halmos; K Szepeshazi; K Groot; K O'Byrne; R Z Cai
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.